Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review (2015-2018)

References

• Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450–6453.
   PubMed Web of Science ®Google Scholar
• Almasri IM, Taha MO, Mohammad MK. New leads for DPP IV inhibition: structure-based pharmacophore mapping and virtual screening study. Arch Pharm Res. 2013;36:1326–1337.
   PubMed Web of Science ®Google Scholar
• Meduru H, Wang YT, Tsai J, et al. Finding a potential dipeptidyl peptidase-4 (DPP-4) inhibitor for type-2 diabetes treatment based on molecular docking, pharmacophore generation, and molecular dynamics simulation. Int J Mol Sci. 2016;17:920–929.
   Web of Science ®Google Scholar
• Abbas G, Hussain H, Hamaed A, et al. The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, α-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2). Bioorg Chem. 2019;86:305–315.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952–957.
   PubMed Web of Science ®Google Scholar
• Fan J, Johnson MH, Lila MA, et al. Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med. 2013;2013:1–13.
   Web of Science ®Google Scholar
• Lambeir AM, Durinx C, Scharpé S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294.
   PubMed Web of Science ®Google Scholar
• Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876–913.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Sato Y, Kamimoto T, et al. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab. 2010;300:E372–379.
   PubMed Web of Science ®Google Scholar
• Andrieu T, Thibault V, Malet I, et al. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J Clin Virol. 2003;27:59–68.
   PubMed Web of Science ®Google Scholar
• Šedo A, Stremenová J, Bušek P, et al. Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opin Med Diagn. 2008;2:677–689.
   PubMedGoogle Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7–18.
   PubMed Web of Science ®Google Scholar
• Rahfeld J, Schutkowski M, Faust J, et al. Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biol Chem Hoppe Seyler. 1991;372(1):313–318.
   PubMedGoogle Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115–121.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122(2):531–544.
   PubMed Web of Science ®Google Scholar
• Li-Chan EC, Hunag SL, Jao CL, et al. Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J Agric Food Chem. 2012;60:973–978.
   PubMed Web of Science ®Google Scholar
• Maturana RL, Willshaw A, Kuntzsch A, et al. The isolated N terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem. 2003;278:10195–10200.
   PubMed Web of Science ®Google Scholar
• Mayo KE, Miller LJ, Bataille D, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55:167–194.
   PubMed Web of Science ®Google Scholar
• Green BD, Flatt PR, Bailey CJ. Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res. 2006;3:159–165.
   PubMedGoogle Scholar
• Xie Y, You Z, He Y, et al. inventor; Sichuan Kelun Pharmaceutical Research Institute Co., Ltd, assignee. 3-Aminotetrahydropyran-pyrrolo[3,4-d]pyrimidine derivatives as longacting dipeptidyl peptidase-IV inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diabetes mellitus and diseases. Patent WO 2017/031918A1.
   Google Scholar
• Li D, inventor; Chengdu Bestchiralbio LLC, assignee. Aminotetrahydropyran derivatives as dipeptidyl peptidase-IV inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. Patent WO 2015/172732A1.
   Google Scholar
• Biftu T, Khan TA, inventor; Merck Sharp & Dohme Corp., assignee. Treating diabetes with dipeptidyl peptidase-iv inhibitors. patent US 2015/0175609A1.
   Google Scholar
• Tang K, inventor; Chengdu Shuoding Technology Co., Ltd., assignee. Dipeptidyl peptidase-IV inhibitor and its preparation. Patent CN106543189A. 2017.
   Google Scholar
• Li D, inventor; Preparation of aminotetrahydropyran derivatives useful as dipeptidyl peptidase-IV inhibitor. patent CN105622612A. 2016.
   Google Scholar
• Fan J, Zhang C, Peng F, et al. inventor; Sichuan Haisco Pharmaceutical Co., Ltd, assignee. Preparation of pyrroloimidazole derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors. Patent WO 2015/192714A1.
   Google Scholar
• Havale SH, Pal M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009;17:1783–1802.
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy-1- adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J Med Chem. 2003;46:2774–2789.
   PubMed Web of Science ®Google Scholar
• Ahren B, Landin-Olsson M, Jansson PA, et al. The DPP IV inhibitor, LAF 237, reduce fasting and postgrandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP 1, sutaining insulin and reducing glucagon. Diabetes. 2003;52:A15.
   Web of Science ®Google Scholar
• Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025–5037.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of  type 2 diabetes. IDrugs. 2008;11:906-917.
   Google Scholar
• Haffner CD, McDougald DL, Randhawa AS, et al. inventor; Smithkline Beecham Corp, assignee. Fluoropyrrolidines as dipeptidyl peptidase inhibitors. Patent WO 2003/002531.
   Google Scholar
• Madar DJ, Kopecka H, Pireh D, et al. Discovery of 2-[4-{{2-(2S,5R)-2-Cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4- pyridinecarboxylic Acid (ABT-279): A Very Potent, Selective, Effective, and Well- Tolerated Inhibitor of Dipeptidyl Peptidase-IV, Useful for the Treatment of Diabetes. J Med Chem. 2006;49:6416–6420.
   PubMed Web of Science ®Google Scholar
• Snow RJ, Bachovchin WW. Boronic acid inhibitors of dipeptidyl peptidase IV: a new class of immunosuppressive agents. Adv Med Chem. 1995;3:149–177.
   Google Scholar
• O’Farrell AM, van Vliet A, Abou Farha K, et al. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther. 2007;29:1692–1705.
   PubMed Web of Science ®Google Scholar
• Gupta R, Walunj SS, Tokala RK, et al. Emerging drug candidates of dipeptidyl peptidase iv (dpp iv) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets. 2009;10:71-87.
   PubMed Web of Science ®Google Scholar
• Ahren B. Dipeptidyl Peptidase-4 Inhibitors; Clinical data and clinical implications. Diabetes Care. 2007;30:1344–1350.
   PubMed Web of Science ®Google Scholar
• Ho KK, Quan W, Zhou J, inventor; Eli Lilly and Company, assignee. Pyrrolidinone compounds as MetAP2 and DPP-4 inhibitors and their preparation. Patent WO 2018/102256A1.
   Google Scholar
• Liao W, Tang L, Zheng P, et al. inventor; Guizhou Medical University, assignee. Xanthine compound and pharmaceutical composition and application thereof. Patent CN 108299436A. 2018.
   Google Scholar
• Meng X Preparation of the quinoline analogues DPP-4 (dipeptidyl peptidase IV) inhibitor. Patent CN 108707143A. 2018.
   Google Scholar
• Meng X, inventor; China, assignee.Dipeptidyl peptidase IV (DPP-4) inhibitor, and its preparation method and application in treating diabetes. Patent CN 108689989A. 2018.
   Google Scholar
• US/EU EudraCT number 2012-004045-33.
   Google Scholar
• Srivastava JK, Dubey P, Singh S, et al. Discovery of novel 1,3,5-triazine-thiazolidine-2,4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of type 2 diabetes. RSC Adv. 2015;5:14095–14102.
   Web of Science ®Google Scholar
• Fouqueray P, Leverve X, Fontaine E, et al. Imeglimin - a new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab. 2011;2:126–133.
   Google Scholar
• Liu G, Li S, Wen X, et al. inventor; Shenzhen Salubris Pharm Co Ltd, assignee. Deuterated 1,2,4-triazine derivatives as dipeptidyl peptidase IV inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. Patent WO 2018/219295A1.
   Google Scholar
• Li D, inventor; Chengdu Beisi Kairui Biolog Technology Co Ltd, assignee. 2-Oxy- 4-thio-3,4-dihydropyrimidine derivative, its preparation method and application as dipeptidyl peptidase IV inhibitor. Patent CN 105272963A. 2016.
   Google Scholar
• Biftu T, inventor; erck Sharp & Dohme Corp., assignee. Treating diabetes with dipeptidyl peptidase-iv inhibitors. Patent US 2015/0225402A1.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical use of berberine sulfate. Patent CN 108635351A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Medicinal use of corybulbine. Patent CN 108635353A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Application of thermopsine in preparing drug for inhibiting dipeptidyl peptidase IV. Patent CN 108403694A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Pharmaceutical application of dihydroarteannuin as inhibitor of dipeptidyl peptidase IV (DPP-IV). Patent CN 108478556A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical application of cucurbitacin L. Patent CN 106963775. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. New drug application of stachydrine in the preparation of dipeptidyl peptidase IV ibitor. Patent CN 108354931A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. New drug application of fagarine in the preparation of dipeptidyl peptidase IV inhibitor. Patent CN 108354937A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. New drug application of artemether in the preparation of dipeptidyl peptidase IV inhibitor. Patent CN108354927A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Use of Decarine as dipeptidyl peptidase inhibitor. Patent CN 107913274A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Norchelerythrine and its application in the manufacture of DPP-IV inhibitor medicament. Patent CN 107875153A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Application of bicuculline as dipeptidyl peptidase IV (DPP-IV) inhibitorin treating type 2 diabetes mellitus and obesity. Patent CN 107823206A. 2018.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Application of hippadine as dipeptidyl peptidase IV (DPP-IV) inhibitor in treating type 2 diabetes mellitus and obesity. Patent CN 107823203A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of taxifolin in preparing dipeptidyl peptidase IV (DPP-IV) inhibitor. Patent CN 107789346A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of syringetin in preparing dipeptidyl peptidase IV inhibitors. Patent CN 107773557A (2018).
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. New application of crebanine in the reparation of dipeptidyl peptidase IV inhibitor. Patent CN 107669680A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of the compound sakuranetin in the preparation of dipeptidyl peptidase IV inhibitors. Patent CN 107648220A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of pachypodol in preparing dipeptidyl peptidase IV inhibitor. CN 107569480A. 2018.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical use of robinetin. Patent CN 107550901A. 2018
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of demethylpericarin in the preparation of dipeptidyl peptidase IV inhibitor drugs. Patent CN 107510693. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Use of tangeretin or pharmaceutically acceptable solvate as dipeptidyl peptidase-IV inhibitors. Patent CN 107510692A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Use of salvigenin or its pharmaceutically acceptable solvate as dipeptidyl peptidase-IV inhibitors. Patent CN 107510691A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Application of bergenin as dipeptidyl peptidase IV inhibitor drug for treating type II diabetes. Patent CN 107496418A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of tamarixetin in preparing dipeptidylpeptidase IV inhibitor. Patnet CN 107496414A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of chrysin as dipeptidyl peptidase IV inhibitor drug for treating type II diabetes. Patent CN 107496409A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of norwogonin as dipeptidyl peptidase IV inhibitor drug for treating type II diabetes. Patent CN 107496408A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical use of myricetin in preparing dipeptidyl peptidase-IV inhibitor. Patent CN 107375267A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical use of wogonin as dipeptidyl peptidase-IV inhibitor. Patent CN 107375266A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Medical application of artemetine in preparation of DPP-IV inhibitor. CN 107375264A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Drug use of phloretin as dipeptidyl peptidase-iv inhibitor. Patent CN 107375256A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Medicinal application of dehydroevodiamine as dipeptidyl peptidase IV inhibitor. Patent CN 107375294A. 2017.
   Google Scholar
• Yuan Q, Liu Y, Cheng H, et al. inventor; Shanghai Yizhi Medicine Tech Co Ltd., assignee. Medicinal use of cucurbitacin B. Patent CN107375302A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical use of epiberberine. Patent CN 107349201A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Pharmaceutical application of saikogenin D. Patent CN 107320476A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Application of corydalmine in preparing dipeptidyl peptidase IV inhibitor. Patent CN 107260738A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Medicinal application of corypalmine as dipeptidyl peptidase-IV (DPP-IV) inhibitor. Patent CN 107260737A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Pharmaceutical application of cucurbitacin E as dipeptidyl peptidase-IV inhibitor. Patent CN 107115348A. 2017.
   Google Scholar
• Shanghai Yizhi Medicine Tech Co Ltd., assignee. Medicinal application of cucurbitacin C as dipeptidyl peptidase-IV inhibitor. Patent CN 107007612A. 2017.
   Google Scholar
• Shanghai Huajin Biotechnology Co Ltd, assignee. Medicinal application of cucurbitacin II B as dipeptidyl peptidase IV inhibitor. Patent CN 106983756A. 2017.
   Google Scholar
• Kim SW, Kim BG, Kim SH, et al. inventor; LG, Chem Ltd., assignee. Composition, kit and combination therapy for treating type-2 diabetes mellitus and diabetic dyslipidemia. Patent KR 2018/002460A.
   Google Scholar
• Fang T, Zhou Y, Jiang M, et al. inventor; Heilongjiang Zbd Pharmaceutical Co Ltd., assignee. Pharmaceutical composition comprising metformin hydrochloride and canagliflozin and/or DPP-4 inhibitor for treating type II diabetes and preparation method thereof. Patent CN 106421794A. 2017.
   Google Scholar
• Zhang L, Yu D, Xu X, et al. inventor; Ausa Pharmed Ltd Shenzhen Ausa Medical Co Ltd., assignee. Pharmaceutical composition containing hypoglycemic medicine, aspirin and folic acid. Patent CN 106310277A. 2017.
   Google Scholar
• Karaagac S, inventor; Turk., assignee. Therapeutic formulations for obesity and type 2 iabetic treatment. Patent TR 2017/000074A2.
   Google Scholar
• Jung IR, Kang SC, inventor; Korea Atomic Energy Research Institute, assignee. Antidiabetic composition comprising Lagerstroemia speciosa extract. Patent KR 2017/043689A.
   Google Scholar
• Matsushima H, Oba T, Hokari Y, et al. inventor; Maruhachi Muramatsu: KK,assignee. Fish-derived composition containing Leu-Arg, DPP-IV inhibitor, use thereof, and manufacturing method therefor. Patent JP 2016/175862A.
   Google Scholar
• Kornev PV, inventor; Promomed Holdings Ltd., assignee. Composition for use in the treatment of disorders associated with overweight or obesity. Patent EA23747B1. 2016.
   Google Scholar
• Kornev PV, inventor; Promomed Holdings Ltd., assignee. Composition for use in the treatment of disorders associated with overweight or obesity. Patent WO 2016/075539A1.
   Google Scholar
• Seki E, Fujiwara Y, Asada H, inventor; Yamaki Co Ltd., assignee. Dipeptidyl aminopeptidase IV inhibitor composition derived from bonito, and its manufacturing method. Patent JP5872725B1. 2016.
   Google Scholar
• Kimura M, Nozaki T, Ishihara T, inventor; BHN Co., Ltd., assignee. GLP-1 production promoter, DPPIV inhibitor, or glucose absorption inhibitor containing Peucedanum japonicum. Patent JP 2016/027042A.
   Google Scholar
• Kodgule MM, Bansal A, Lalge M, inventor; Wockhardt Ltd., assignee. A novel modified release pharmaceutical composition of DPP-IV inhibitors or pharmaceutically acceptable salt thereof. Patent IN2014MU02422A; 2016.
   Google Scholar
• Kodgule MM, Bansal A, Lalge M, inventor; Wockhardt Ltd., assignee. A novel modified release pharmaceutical composition of DPP-IV inhibitors or pharmaceutically acceptable salt thereof. Patent WO 2016/016772A1.
   Google Scholar
• Arora VK, Venkateshwaran R, Madan S, inventor; Ranbaxy Lab Ltd., assignee. Oral ispersible composition of a DPP-IV inhibitor for treating diabetes. Patent WO 2015/071859A1.
   Google Scholar
• Ma Y, Yuan J, inventor; Shenzhen Hybio Pharmaceutical, assignee. Pharmaceutical composition containing GLP-1 analogues and DPP-4 inhibitors and preparation method thereof. Patent CN 104548096A. 2015.
   Google Scholar
• Miao C, Li Z, Guan Y, inventor; University Pla 2nd Military Medical, assignee. Pharmaceutical composition containing immunoglobulin G for treating obesity and its application. Patent CN 104524568A. 2015.
   Google Scholar
• Arora VK, Madan S, Venkateshwaran R, inventor; Ranbaxy Lab Ltd., assignee. Oral liquid pharmaceutical composition of a DPP-IV inhibitor. Patent WO 2015/044880A1.
   Google Scholar
• Song JK, Chang EJ, inventor; The Asan Foundation, assignee. Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor. Patent US 2015/0065693A1.
   Google Scholar
• Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5:138–146.
   PubMedGoogle Scholar
• Li N, Wang LJ, Jiang B, et al. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. Bioorg Med Chem Lett. 2018;28:2131–2135.
   PubMedGoogle Scholar
• Kshirsagar AD, Aggarwal AS, Harle UN, et al. DPP IV inhibitors: successes, failures and future prospects. Diabetes Metab Syndrome: Clin Res Rev. 2011;5:105–112.
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2014;37:S14–S80.
   PubMed Web of Science ®Google Scholar
• Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res. 2008;41:69–77.
   PubMed Web of Science ®Google Scholar
• Vijayakrishnan R. Structure-based drug design and modern medicine. J Postgrad Med. 2009;55:301–304.
   PubMed Web of Science ®Google Scholar
• Talele TT, Khedkar SA, Rigby AC. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem. 2010;10:127–141.
   PubMed Web of Science ®Google Scholar
• Van Drie JH. Computer-aided drug design: the next 20 years. J Comput Aided Mol Des. 2007;21:591–601.
   PubMed Web of Science ®Google Scholar
• Tanwar O, Tanwar L, Shaquiquzzaman M, et al. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors. Bioorg Med Chem Lett. 2014;24:3447–3451.
   PubMed Web of Science ®Google Scholar